The following discussion and analysis should be read together with our condensed
unaudited financial statements and the related notes appearing elsewhere in this
quarterly report on Form 10-Q and with the audited financial statements and
notes for the fiscal year ended December 31, 2019, and the information under the
headings "Risk Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" in our Annual Report on Form 10-K filed
with the SEC on March 9, 2020, or the Annual Report. This discussion contains
forward-looking statements reflecting our current expectations that involve
risks and uncertainties. See "Cautionary Note Regarding Forward-Looking
Statements" for a discussion of the uncertainties, risks and assumptions
associated with these statements. Actual results and the timing of events could
differ materially from those discussed in our forward-looking statements as a
result of many factors, including those set forth under "Risk Factors" in our
Annual Report.
Overview
We are a company providing technology solutions to improve the clinical
effectiveness and efficiency of healthcare providers. Our mission is to develop,
manufacture and market innovative proprietary products and services that assist
our customers in evaluating and treating chronic diseases. In 2011, we began
commercializing our first patented and U.S. Food and Drug Administration, or
FDA, cleared product, which measured arterial blood flow in the extremities to
aid in the diagnosis of peripheral arterial disease, or PAD. In March 2015, we
received FDA 510(k) clearance for the next generation version of our product,
QuantaFlo®, which we began commercializing in August 2015. We believe our
products and services position us to provide valuable information to our
customer base, which in turn permits them to better guide patient care.
In the three months ended March 31, 2020, we had total revenues of $9,430,000
and net income of $2,673,000, compared to total revenues of $6,761,000 and net
income of $1,854,000 in the same period in 2019.
Recent Developments
In the first quarter of 2020, new installations produced an overall net gain in
fixed-fee license contracts. Requests for changes in billing arrangements in the
quarter due to COVID-19 amounted to less than 1% of fixed-fee license contracts
for QuantaFlo®.
Because we started to experience the effects of COVID-19 late in the first
quarter, results in the first quarter are not indicative of any future quarter
or the full fiscal year results. Test volumes have decreased due to "social
distancing" and other executive orders mandating "shelter in place" or similar
restrictions. This affects revenues from our variable-monthly fee arrangements,
which are based on usage largely occurring during home visits.
In April 2020 compared to March 2020, fixed-fee monthly license revenues
decreased by approximately 4% and variable fee software license revenues
decreased by approximately 97%.
Although we do not provide formal guidance, we intend to manage our expenses and
other costs in line with changes in revenues to conservatively preserve cash
during these uncertain times. We believe customer interest in our QuantaFlo®
product and related services will return to, or exceed, pre-COVID-19 activity at
such time as "shelter-in place" or similar restrictions are lifted and
non-emergency medical services resume.
Operating expenses are expected to decrease during the second quarter of 2020 as
a result of cost-cutting measures that have included vendor fee reductions and
decreased spending on consultants. To date, staffing, salaries and inventory
have been maintained at usual levels, and travel expenses have decreased. Cash
at April 30, 2020 increased compared to cash at March 31, 2020 primarily due to
these cost-cutting measures, which have decreased our monthly operating
expenses.
Until the effects of the COVID-19 pandemic on our business are more
quantifiable, we do not plan to undertake any material changes to our business
plan or operations.
Results of Operations
Three Months Ended March 31, 2020 Compared to Three Months Ended March 31, 2019
Revenues
We had revenues of $9,430,000 for the three months ended March 31, 2020, an
increase of $2,669,000, or 39%, compared to $6,761,000 in the same period in
2019. Our revenues are primarily from fees charged to customers for use of our
vascular testing products and from sale of accessories used with these products.
We recognized revenues of $9,160,000 from fees for our vascular testing products
for the three months ended March 31, 2020, an increase of $2,645,000 compared to
$6,515,000 in the same period of the prior year. The remainder was from other
items, such as the sale of equipment, supplies or accessories sales, which were
$270,000 in the three months ended March 31, 2020, as compared to $246,000 in
the same period of the prior year.
10
Revenues from fees for vascular testing products are recognized monthly for each
unit installed with a customer, usually billed as a fixed monthly fee or as a
variable monthly fee dependent on usage. The primary reason for the increase in
revenues was growth in the number of installed units from both new customers and
established customers, which we believe is the result of our sales and marketing
efforts.
Operating expenses
We had total operating expenses of 5,978,000 for the three months ended March
31, 2020, an increase of $1,071,000 or 22%, compared to $4,907,000 in the same
period in the prior year. The primary reason for this change was overall growth
in our business, increased compensation of the sales team and increased
headcount of field sales and technical support personnel to service the
expanding number of customers. As a percentage of revenues, operating expenses
decreased to 63% as compared to 73%. The changes in the various components of
our operating expenses are described below.
Cost of revenues
We had cost of revenues of $850,000 for the three months ended March 31, 2020, a
decrease of $46,000, or 5%, compared to $896,000 in the same period of the prior
year. The primary reason for this change was lower depreciation per unit per
month as a greater percentage of installations were software and sensor only
rather than laptop, software and sensor, as well as lower residual value for
retired units. As a percentage of revenues, cost of revenues decreased to 9%, as
compared to 13%, primarily due to revenues growing at a faster pace than cost of
revenues.
Engineering and product development expense
We had engineering and product development expense of $842,000 for the three
months ended March 31, 2020, an increase of $273,000, or 48%, compared to
$569,000 in the same period of the prior year. The increase was primarily due to
timing of consultant costs, personnel and other costs associated with our
product development and customization efforts. As a percentage of revenues,
engineering and product development expense decreased to 9%, as compared to 8%.
Sales and marketing expense
We had sales and marketing expense of $2,695,000 for the three months ended
March 31, 2020, an increase of $625,000, or 30%, compared to $2,070,000 in the
same period of the prior year. The increase was primarily due to higher sales
compensation and personnel expense and the continued expansion of existing
customer orders, marketing activities and increased headcount and associated
expense. As a percentage of revenues, sales and marketing expense decreased to
29%, as compared to 31%.
General and administrative expense
We had general and administrative expense of $1,591,000 for the three months
ended March 31, 2020, an increase of $219,000, or 16%, compared to $1,372,000 in
the same period of the prior year. The increase was primarily due to the growth
in our business, which led to increased expenses to support a growing company,
including higher infrastructure costs, insurance and other professional fees, as
well as higher compensation and personnel expense. As a percentage of revenues,
general and administrative expense decreased to 17%, as compared to 20%.
Other expense
We had other expense of $2,000 for the three months ended March 31, 2020,
compared to no other expense in the same period of the prior year. The increase
was primarily due to credit card fees, partially offset by interest income.
Pre-tax net income
For the foregoing reasons, we had pre-tax net income of $3,450,000, or $0.53 per
basic share and $0.43 per diluted share, for the three months ended March 31,
2020, an increase of $1,596,000, or 86%, compared to a pre-tax net income of
$1,854,000, or $0.29 per basic share and $0.23 per diluted share, for the same
period of the prior year.
11
Income tax expense
We had income tax expense of $777,000 for the three months ended March 31, 2020,
compared to no income tax expense in the same period of the prior year. The
increase was primarily due to amortization of our deferred tax asset.
Net income
For the foregoing reasons, we had net income of $2,673,000, or $0.41 per basic
share and $0.33 per diluted share, for the three months ended March 31, 2020, an
increase of $819,000, or 44%, compared to a net income of $1,854,000, or $0.29
per basic share and $0.23 per diluted share, for the same period of the prior
year.
Liquidity and Capital Resources
We had cash of $11,214,000 at March 31, 2020 compared to $7,741,000 at
December 31, 2019, and total current liabilities of $3,820,000 at March 31, 2020
compared to $5,207,000 at December 31, 2019. As of March 31, 2020, we had
working capital of approximately $9,663,000.
Our cash is held in a variety of non-interest bearing bank accounts and
interest-bearing instruments subject to investment guidelines allowing for
holdings in U.S. government and agency securities, corporate securities, taxable
municipal bonds, commercial paper and money market accounts. In addition, we may
also choose to invest some of our cash resources in other entities that may have
complementary technologies or product offerings
Operating activities
We generated $3,742,000 of net cash from operating activities for the three
months ended March 31, 2020 compared to $1,703,000 of net cash from operating
activities for the same period of the prior year. The improvement was primarily
due to changes in net income, as well as both non-cash adjustments and operating
assets and liabilities, which occurred due to growth in our business. Non-cash
adjustments to reconcile net income to net cash from operating activities were
$1,044,000. These non-cash adjustments were primarily due to deferred tax
expense of $721,000, depreciation of assets for lease of $128,000, stock-based
compensation expense of $67,000, loss on disposal of assets for lease of
$66,000, fixed assets depreciation and amortization of $31,000 and allowance for
bad debt expense of $31,000. Changes in operating assets and liabilities
provided $25,000 of net cash. These changes in operating assets and liabilities
included cash provided by trade accounts receivable of $1,875,000, accounts
payable of $39,000 and deferred revenue of $34,000, partially offset by cash
used by accrued expenses of $1,466,000 and prepaid expenses of $457,000.
Investing activities
We used $272,000 of net cash in investing activities for the three months ended
March 31, 2020, which reflects purchases of assets for lease of $181,000 and
fixed asset purchases of $91,000 to support our growing business.
We used $456,000 of net cash in investing activities for the three months ended
March 31, 2019, which reflects purchases of assets for lease of $425,000 and
fixed asset purchases of $31,000 to support our growing business.
Financing activities
We generated $3,000 in net cash from financing activities during the three
months ended March 31, 2020, primarily due to proceeds from exercise of stock
options.
We generated $13,000 in net cash from financing activities during the three
months ended March 31, 2019, primarily due to proceeds from exercise of stock
options.
Off-Balance Sheet Arrangements
As of each of March 31, 2020 and December 31, 2019, we had no off-balance sheet
arrangements.
Commitments and Contingencies
As of each of March 31, 2020 and December 31, 2019, other than
employment/consulting agreements with key executive officers and our facilities
lease obligation, we had no material commitments other than the liabilities
reflected in our financial statements.
12
© Edgar Online, source Glimpses